Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we p...

Full description

Bibliographic Details
Main Authors: Anna Kreutzman, Bhagwan Yadav, Tim H. Brummendorf, Bjorn Tore Gjertsen, Moon Hee Lee, Jeroen Janssen, Tiina Kasanen, Perttu Koskenvesa, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Jesper Stentoft, Leif Stenke, Stina Söderlund, Lene Udby, Johan Richter, Henrik Hjorth-Hansen, Satu Mustjoki
Format: Article
Language:English
Published: Taylor & Francis Group 2019-09-01
Series:OncoImmunology
Subjects:
cml
imatinib
bosutinib
sokal
bcr-abl
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1638210

Internet

http://dx.doi.org/10.1080/2162402X.2019.1638210

Similar Items